EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad iD, Egils Vjaters iD, Neal Shore iD, David Olmos iD, Nianzeng Xing iD, Andrea Juliana Pereira de Santana Gomes iD, Augusto Cesar de Andrade Mota iD, Pamela Salman iD, Mindaugas Jievaltas, Albertas Ulys, Maris Jakubovskis, Evgeny Kopyltsov und 7 weitere

Journal of Clinical Oncology · 20.12.2024 · 42 (36) · 4271-4281

DOI: 10.1200/jco-24-01798 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.12.2024. Verfasst von Fred Saad und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery/Urology, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pyrazoles, Androgen Antagonists. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without chemotherapy in patients with mHSPC. METHODS In this global phase III trial, patients were randomly assigned 2:1 to receive darolutamide 600 mg twice daily or placebo, with concomitant ADT. The primary end point was radiological progression-free survival (rPFS). RESULTS From March 2021 to August 2022, 669 patients were randomly assigned (darolutamide n = 446; placebo n = 223). At the primary cutoff date (June 7, 2024), darolutamide plus ADT significantly improved rPFS, reducing the risk of radiological progression or death by 46% versus placebo plus ADT (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.71]; P < .0001), with consistent benefits across subgroups, including high- and low-volume disease. OS results were suggestive of benefit with darolutamide versus placebo (HR, 0.81 [95% CI, 0.59 to 1.12]), and clinical benefits were seen across all other secondary end points, including delayed time to metastatic castration-resistant prostate cancer (HR, 0.40 [95% CI, 0.32 to 0.51]) and time to pain progression (HR, 0.72 [95% CI, 0.54 to 0.96]). Adverse events were similar in the two groups. Notably, the incidence of fatigue was lower in patients receiving darolutamide (5.6%) versus those receiving placebo (8.1%), and fewer patients receiving darolutamide (6.1%) versus placebo (9.0%) discontinued treatment because of adverse events. CONCLUSION These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase III darolutamide trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPyrazolesAndrogen AntagonistsHumansMaleAgedMiddle AgedDouble-Blind MethodProgression-Free SurvivalProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAged, 80 and overSulfonamides

Substanzen

darolutamidePyrazolesAndrogen AntagonistsSulfonamides

Autor:innen und Institutionen

  • Department of Surgery/Urology, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
  • P. Stradinš Clinical University Hospital, Riga, Latvia.
  • Carolina Urologic Research Center and AUC Urology Specialists, Myrtle Beach, SC.
  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas 12), Madrid, Spain.
  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liga Norte Riograndense Contra O Cancer, Natal, Brazil.

ORCID-Profile: Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing, Andrea Juliana Pereira de Santana Gomes, Augusto Cesar de Andrade Mota, Pamela Salman

Zitieren

APA

Saad, F., Vjaters, E., Shore, N., Olmos, D., Xing, N., Pereira de Santana Gomes, A. J., Cesar de Andrade Mota, A., Salman, P., Jievaltas, M., Ulys, A., Jakubovskis, M., Kopyltsov, E., Han, W., Nevalaita, L., Testa, I., Le Berre, M. A., Kuss, I., Haresh, K. P., & ARANOTE Study Investigators (2024). Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. Journal of Clinical Oncology, 42(36), 4271-4281. https://doi.org/10.1200/jco-24-01798

Vancouver

Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. Journal of Clinical Oncology. 2024;42(36):4271-4281. doi:10.1200/jco-24-01798

BibTeX
@article{Saad2024,
  author = {Saad, Fred and Vjaters, Egils and Shore, Neal and Olmos, David and Xing, Nianzeng and Pereira de Santana Gomes, Andrea Juliana and Cesar de Andrade Mota, Augusto and Salman, Pamela and Jievaltas, Mindaugas and Ulys, Albertas and Jakubovskis, Maris and Kopyltsov, Evgeny and Han, Weiqing and Nevalaita, Liina and Testa, Isabella and Le Berre, Marie-Aude and Kuss, Iris and Haresh, Kunhi Parambath and ARANOTE Study Investigators, ARANOTE Study Investigators},
  title = {Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {36},
  pages = {4271--4281},
  doi = {10.1200/jco-24-01798}
}
Kostenlos starten →